Table 2.

Response rates in both treatment arms during the course of the study, number of patients (%).

Treatment armA: 25 mgB: 5 mg
AfterRANDLenCTLenMTRANDLenCTLenMT
Time (years)00.5123Best00.5123Best
sCR6 (6)22 (23)28 (30)20 (21)14 (15)34 (36)8 (9)18 (19)17 (18)14 (15)12 (13)22 (23)
CR9 (10)11 (12)12 (13)7 (7)4 (4)13 (14)18 (19)20 (21)16 (17)12 (13)6 (6)23 (24)
vgPR46 (49)33 (35)20 (21)12 (13)6 (6)29 (31)35 (37)25 (27)11 (12)7 (7)3 (3)26 (28)
PR27 (29)20 (21)13 (14)10 (11)5 (5)15 (16)30 (32)23 (24)13 (14)7 (7)2 (2)22 (23)
MR or SD6 (6)4 (4)4 (4)3 (3)2 (2)3 (3)3 (3)2 (2)1 (1)1 (1)0 (0)1 (1)
Off studya0 (0)4 (4)17 (17)30 (32)37 (39)-0 (0)6 (6)34 (35)43 (46)52 (56)-
Active patientsb0 (0)0 (0)0 (0)12 (13)26 (28)-0 (0)(0)2 (2)10 (10)19 (20)-
  • Abbreviations: (s)CR, (stringent) complete response; MR, minimal response; RAND, randomization; SD, stable disease.

  • aOff study because of progressive disease, death, or lost to follow up.

  • bActive patients in remission, who have not completed this time point at the time of analysis.